Patient dosing completed in collaborator-sponsored Phase 1/2 clinical trial for cystinosis
Rare pediatric disease designations received for Gaucher disease and cystinosis investigational gene therapies
Comprehensive Gaucher disease program update planned for Wednesday, Dec. 7
CAMBRIDGE, Mass.–(BUSINESS WIRE)–$AVRO—AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the third quarter ended Sept. 30, 2022 and provided a business update.
“We had a steady cadence of news this quarter highlighting our steadfast efforts to bring our gene therapies to patients,” said Geoff MacKay, president and CEO of AVROBIO. “We look forward to providing a comprehensive update next month on our HSC gene therapy targeting Gaucher disease, the most common lysosomal disorder, impacting an estimated 30,000 patients worldwide. This update will contain interim clinical data from our Gaucher disease type 1 Phase 1/2 trial, including data out over two years. Notably, we plan to provide an update on our regulatory interactions for a planned Gaucher disease type 3 clinical study, as well as our overall Gaucher clinical development strategy.”
Program Updates
AVR-RD-02 in Gaucher disease:
- Received rare pediatric disease designation (RPDD) from the U.S. Food and Drug Administration (FDA). Read full press release here
- Received Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA). Read full press release here
- AVR-RD-02 previously has been granted Fast Track status from FDA and orphan drug designation (ODD) in the U.S. and EU
AVR-RD-04 in cystinosis:
- Patient dosing completed in collaborator-sponsored Phase 1/2 trial. Interim efficacy data from first five patients show systemic gene therapy effect across multiple tissues evaluated, including peripheral blood leukocytes, eyes, skin, gastrointestinal mucosa and neurocognitive system. Read full press release here
- Received RPDD for AVR-RD-04 from FDA. Read full press release here
- AVR-RD-04 previously has been granted ODD in the U.S. and EU
- Submitted a meeting request to the MHRA to discuss a company-sponsored clinical trial for AVR-RD-04 and expect a scientific advice meeting with MHRA in Q1 2023; planning to engage with other regulatory authorities as we expand this anticipated global trial
AVR-RD-05 in Hunter syndrome:
- Clinical trial application (CTA) approved by the MHRA, Research Ethics Committee and Health Research Authority for a Phase 1/2 clinical trial in infants diagnosed with neuronopathic mucopolysaccharidosis type II (nMPS-II) or Hunter syndrome. AVROBIO’s collaborators at the University of Manchester, U.K., expect to dose the first patient in the trial in 1H 2023. Read full press release here
- AVR-RD-05 previously has been granted RPDD and ODD in the U.S.
Presented positive data on the combined use of two state-of-the-art assays to evaluate the genotoxicity risk of integrating vectors during preclinical development, at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), Oct. 11-14, 2022 in Edinburgh, Scotland
- Read the full press release here
Gaucher disease program update planned for Dec. 7, 2022
The company will provide an update to investors on its Gaucher disease program, including new and updated data from the Guard1 Phase 1/2 clinical trial of AVR-RD-02 for Gaucher disease type 1 and an update on regulatory interactions for a planned Gaucher disease type 3 clinical study, as well as the overall Gaucher clinical development strategy. More information on this virtual event will follow in the next few weeks and will be posted on the corporate website ahead of the event.
Third Quarter 2022 Financial Results
AVROBIO reported a net loss of $23.0 million for the third quarter of 2022 as compared to a net loss of $32.6 million for the comparable period in 2021. This decrease was driven by a reduction in research and development expenses.
Research and development expenses were $15.9 million for the third quarter of 2022 as compared to $23.0 million for the comparable period in 2021. This decrease was driven by a reduction in program development expenses and personnel-related costs, including non-cash stock-based compensation.
General and administrative expenses were $7.1 million for the third quarter of 2022 as compared to $9.6 million for the comparable period in 2021. This decrease was attributable to a decrease in personnel-related costs, including non-cash stock-based compensation, and a decrease in other expenses, primarily related to facilities costs and professional fees.
Other income (expense), net was less than $0.1 million in income for the third quarter of 2022 as well as for the comparable period in 2021.
As of September 30, 2022, AVROBIO had $116.0 million in cash and cash equivalents, as compared to $189.6 million in cash and cash equivalents as of December 31, 2021. Based on AVROBIO’s current operating plan, AVROBIO expects its cash and cash equivalents as of September 30, 2022, will enable AVROBIO to fund its operating expenses and capital expenditure requirements into the first quarter of 2024.
About AVROBIO
Our vision is to bring personalized gene therapy to the world. We target the root cause of genetic disease by introducing a functional copy of the affected gene into patients’ own hematopoietic stem cells (HSCs), with the goal to durably express the therapeutic protein throughout the body, including the central nervous system. Our first-in-class pipeline includes clinical programs for cystinosis and Gaucher disease type 1, as well as preclinical programs for Gaucher disease type 3, Hunter syndrome and Pompe disease. Our proprietary plato® gene therapy platform is designed to be scaled to support late-stage clinical development and commercialization globally. We are headquartered in Cambridge, Mass. For additional information, visit avrobio.com and follow us on Twitter and LinkedIn.
Forward-Looking Statement
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “aims,” “anticipates,” “believes,” “could,” “designed to,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words and phrases or similar expressions that are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding our business strategy for and the potential therapeutic benefits of our current and prospective product candidates, the expected safety profile of our investigational gene therapies, results of preclinical studies, the design, commencement, enrollment and timing of ongoing or planned clinical trials, clinical trial results, product approvals and regulatory pathways, the timing of patient recruitment and enrollment activities, our plans and expectations with respect to interactions with regulatory agencies and the timing and likelihood of success thereof, the expected benefits and results of our implementation of the plato® platform in our clinical trials and gene therapy programs and its potential impact on our manufacturing and commercialization activities, and statements regarding our financial and cash position and expected cash runway, including impact on anticipated milestones. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Results in preclinical or early-stage clinical trials may not be indicative of results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented.
Any forward-looking statements in this press release are based on AVROBIO’s current expectations, estimates and projections about our industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that any one or more of AVROBIO’s product candidates will not be successfully developed or commercialized, the risk of cessation or delay of any ongoing or planned clinical trials of AVROBIO or our collaborators, the risk that AVROBIO may not successfully recruit or enroll a sufficient number of patients for our clinical trials, the risk that AVROBIO may not realize the intended benefits of our gene therapy platform, including the features of our plato® platform, the risk that our product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that we anticipate, the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or trials involving AVROBIO’s product candidates, the risk that we will be unable to obtain and maintain regulatory approval for our product candidates, the risk that we may be unable to realize the potential benefits associated with rare pediatric disease designation, the Innovative Licensing and Access Pathway, or any other regulatory strategy, the risk that the size and growth potential of the market for our product candidates will not materialize as expected, risks associated with our dependence on third-party suppliers and manufacturers, including sole source suppliers, risks regarding the accuracy of our estimates of expenses and future revenue, risks relating to our capital requirements and needs for additional financing, risks relating to clinical trial and business interruptions resulting from the COVID-19 outbreak or similar public health crises, including that such interruptions may materially delay our enrollment and development timelines and/or increase our development costs or that data collection efforts may be impaired or otherwise impacted by such crises, and risks relating to our ability to obtain and maintain intellectual property protection for our product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause AVROBIO’s actual results to differ materially and adversely from those contained in the forward-looking statements, see the section entitled “Risk Factors” in AVROBIO’s most recent Annual or Quarterly Report, as well as discussions of potential risks, uncertainties and other important factors in AVROBIO’s subsequent filings with the Securities and Exchange Commission. AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
|
CONDENSED CONSOLIDATED BALANCE SHEETS |
|||||||||
|
September 30, |
December 31, |
||||||||
|
2022 |
2021 |
||||||||
|
|
|
|
|||||||
|
Cash and cash equivalents |
$ |
115,968 |
|
$ |
189,567 |
||||
|
Prepaid expenses and other current assets |
|
9,773 |
|
|
9,578 |
||||
|
Property and equipment, net |
|
3,223 |
|
|
4,126 |
||||
|
Other assets |
|
533 |
|
|
566 |
||||
|
Total assets |
$ |
129,497 |
|
$ |
203,837 |
||||
|
|
|
|
|
||||||
|
Accounts payable |
$ |
1,814 |
|
$ |
3,486 |
||||
|
Accrued expenses and other current liabilities |
|
14,378 |
|
|
15,900 |
||||
|
Note payable, net of discount |
|
15,205 |
|
|
14,945 |
||||
|
Deferred rent, net of current portion |
|
10 |
|
|
30 |
||||
|
Total liabilities |
$ |
31,407 |
|
$ |
34,361 |
||||
|
|
|
|
|
||||||
|
Total stockholders’ equity |
|
98,090 |
|
|
169,476 |
||||
|
Total liabilities and stockholders’ equity |
$ |
129,497 |
|
$ |
203,837 |
||||
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
||||||||||||||||||
|
|
Three Months Ended |
|
Nine Months Ended |
|||||||||||||||
|
|
2022 |
|
2021 |
|
2022 |
|
2021 |
|||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
|
Operating expenses: |
|
|
|
|
|
|
|
|||||||||||
|
Research and development |
$ |
15,919 |
|
|
$ |
23,043 |
|
|
$ |
54,049 |
|
|
$ |
64,114 |
|
|||
|
General and administrative |
|
7,066 |
|
|
|
9,577 |
|
|
|
26,128 |
|
|
|
26,765 |
|
|||
|
Total operating expenses |
|
22,985 |
|
|
|
32,620 |
|
|
|
80,177 |
|
|
|
90,879 |
|
|||
|
|
|
|
|
|
|
|
|
|||||||||||
|
Loss from operations |
|
(22,985 |
) |
|
|
(32,620 |
) |
|
|
(80,177 |
) |
|
|
(90,879 |
) |
|||
|
Other income (expense), net |
|
16 |
|
|
|
7 |
|
|
|
(679 |
) |
|
|
(20 |
) |
|||
|
Net loss |
($ |
22,969 |
) |
|
($ |
32,613 |
) |
|
($ |
80,856 |
) |
|
($ |
90,899 |
) |
|||
|
Net loss per share — basic and diluted |
($ |
0.52 |
) |
|
($ |
0.75 |
) |
|
($ |
1.85 |
) |
|
($ |
2.13 |
) |
|||
|
Weighted-average number of common shares outstanding — basic and diluted |
|
43,773 |
|
|
|
43,623 |
|
|
|
43,722 |
|
|
|
42,588 |
|
|||
Contacts
Investor Contact:
Christopher F. Brinzey
Westwicke, an ICR Company
339-970-2843
chris.brinzey@westwicke.com
Media Contact:
Kit Rodophele
Ten Bridge Communications
617-999-9620
krodophele@tenbridgecommunications.com